Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Novartis
74 Articles Available
0
4
Can't find what you're looking for? Try our
advanced search
.
Oral Therapy
Novartis Investigational Oral Therapy Iptacopan (Lnp023) Shows Benefit as Monotherapy in Treatment-Naïve Patients with Rare and Life-threatening Blood Disorder Paroxysmal Nocturnal Hemoglobinuria
PR-M06-21-022
COVID-19 Treatment
Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for Ensovibep for the Treatment of COVID-19
PR-M06-21-003
FDA Approval
Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis
PR-M06-21-002
Production
Novartis to Produce Roche's Actemra/RoActemra
PR-M04-21-017
Novartis Announces Collaboration with Molecular Partners to Develop Two DARPin Therapies for Potential Use Against COVID-19
PR-M11-20-006
Antibiotics
Sandoz Announces Plans for Joint Investment to Help Strengthen Future of Antibiotics Manufacturing in Europe
PR-M07-20-NI-38
Novartis Launches First-of-its-Kind Not-for-Profit Portfolio of Medicines for Symptomatic Treatment of COVID-19
PR-M07-20-NI-35
COVID Vaccine
AAVCOVID Vaccine Program from Mass. Eye and Ear and Mass General Enters Manufacturing Agreement with Gene Therapy Leader AveXis, a Novartis Company
PR-M05-20-NI-042
FDA Approval
Novartis Announces FDA Approval of MET Inhibitor Tabrecta™ for Metastatic Non-Small Cell Lung Cancer with METex14
PR-M05-20-NI-011
M&A
Novartis Acquires Amblyotech
PR-M04-20-NI-039
COVID-19 Clinical Trials
Novartis to Sponsor Large Clinical Trial of Hydroxychloroquine in Hospitalized COVID-19 Patients
PR-M04-20-NI-029
COVID-19 Clinical Study
Novartis Announces Plans to Initiate Clinical Study of Jakavi in Severe COVID-19 Patients
PR-M04-20-NI-016
Priority Review
Novartis Lung Cancer Drug Granted Priority FDA Review
PR-M02-20-NI-010
M&A
Novartis to Acquire The Medicines Company for $9.7 Billion
PR-M11-19-NI-031
Approval
Novartis Gets European Approval to Update Cosentyx Label to Include Dosing Flexibility in Ankylosing Spondylitis
PR-M10-19-NI-036
Collaboration
Novartis and Microsoft Announce Collaboration to Transform Medicine with Artificial Intelligence
PR-M10-19-NI-007
Data Integrity
Novartis Pledges 5-Day Response Regarding Future Data Integrity Issues
PAO-M09-19-NI-020
M&A
Zhejiang Jiuzhou to Acquire Suzhou Unit of Novartis AG for CNY790 Million
PAO-M09-19-NI-009
Novartis Stands Behind Zolgensma® (onasemnogene abeparvovec-xioi) for the Treatment of Children Less than 2 Years of Age with Spinal Muscular Atrophy
PR-M08-19-NI-023
Drug Pricing
CAR-T Cell Therapy Price Sets Record in Switzerland
PAO-M07-19-NI-018
FDA Acceptance
FDA Accepts File and Accelerates Review of Novartis Sickle Cell Disease Medicine Crizanlizumab (SEG101)
PR-M07-19-NI-048
Acquisition
Recordati to Acquire Worldwide Rights to Signifor® and Osilodrostat (Lci699)
PR-M07-19-NI-041
Acquisition
Lonza Will Purchase a Sterile Fill-Finish Site from Novartis
PAO-M07-19-NI-012
M&A
Lonza to Acquire Sterile Fill and Finish Facility from Novartis
PR-M07-19-NI-010
«
0
4
»
.svg)